Furmonertinib in First-line Treatment of Patients With CNS Metastatic EGFR Mutation Positive NSCLC
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
EGFR mutation positive advanced NSCLC patients with CNS metastases have poor prognosis,
second-line furmonertinib dose at 160mg level in EGRF T790M mutation positive CNS metastatic
NSCLC have provided relevant benefit with a high CNS PFS and CNS ORR. Whether CNS metastatic
EGFR mutation positive NSCLC patients can benefit from first-line furmonertinib 160mg per day
has not been reported. This study aims to investigate the efficacy and safety of
furmonertinib 160mg per day in CNS metastatic EGFR mutant patients under first-line treatment
of advanced NSCLC setting.